Titan Pharmaceuticals, Inc. (AMEX: TTP)

Titan Pharmaceuticals, Inc. (AMEX: TTP) has their focus on the late-stage development and commercialization of innovative treatments for central nervous system disorders. In addition to their first product in clinical testing, Probuphine, the Company has plans to develop its ProNeura sustained drug delivery technology for other potential treatment applications where conventional treatment is limited by inconsistency in blood drug levels and poor patient compliance. For further information, visit the Company’s web site at www.titanpharm.com.